{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:37:23Z","timestamp":1786358243246,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":51,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-58915-y","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T08:25:04Z","timestamp":1781943904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advanced glycation end products and the CALLY index reflect inflammatory burden in familial Mediterranean fever"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7220-0288","authenticated-orcid":false,"given":"Altu\u011f","family":"G\u00fcner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00fcmeyye Tuna","family":"G\u00fcner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"key":"58915_CR1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3389\/fimmu.2017.00253","volume":"8","author":"S Ozen","year":"2017","unstructured":"Ozen, S., Batu, E. D. & Demir, S. Familial Mediterranean fever: recent developments in pathogenesis and new recommendations for management. Front. Immunol. 8, 253. https:\/\/doi.org\/10.3389\/fimmu.2017.00253 (2017).","journal-title":"Front. Immunol."},{"key":"58915_CR2","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/art.24458","volume":"61","author":"E Ben-Chetrit","year":"2009","unstructured":"Ben-Chetrit, E. & Touitou, I. Familial Mediterranean fever in the world. Arthritis Rheum. 61, 1447\u20131453. https:\/\/doi.org\/10.1002\/art.24458 (2009).","journal-title":"Arthritis Rheum."},{"key":"58915_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.md.0000152370.84628.0c","volume":"84","author":"Turkish FMF Study Group","year":"2005","unstructured":"Turkish FMF Study Group. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Med. (Baltim). 84, 1\u201311. https:\/\/doi.org\/10.1097\/01.md.0000152370.84628.0c (2005).","journal-title":"Med. (Baltim)."},{"key":"58915_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nrrheum.2010.186","volume":"7","author":"I Ben-Zvi","year":"2011","unstructured":"Ben-Zvi, I. & Livneh, A. Chronic inflammation in familial Mediterranean fever. Nat. Rev. Rheumatol. 7, 105\u2013110. https:\/\/doi.org\/10.1038\/nrrheum.2010.186 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"58915_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12621","volume":"281","author":"CA Dinarello","year":"2018","unstructured":"Dinarello, C. A. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol. Rev. 281, 8\u201327. https:\/\/doi.org\/10.1111\/imr.12621 (2018).","journal-title":"Immunol. Rev."},{"key":"58915_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11892-014-0453-1","volume":"14","author":"H Vlassara","year":"2014","unstructured":"Vlassara, H. & Uribarri, J. Advanced glycation end products and diabetes: cause, effect, or both? Curr. Diabetes Rep. 14, 453. https:\/\/doi.org\/10.1007\/s11892-014-0453-1 (2014).","journal-title":"Curr. Diabetes Rep."},{"key":"58915_CR7","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1089\/rej.2006.9.264","volume":"9","author":"VM Monnier","year":"2006","unstructured":"Monnier, V. M. & Sell, D. R. Prevention and repair of protein damage by the Maillard reaction in vivo. Rejuvenation Res. 9, 264\u2013273. https:\/\/doi.org\/10.1089\/rej.2006.9.264 (2006).","journal-title":"Rejuvenation Res."},{"key":"58915_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0167-4889(00)00087-2","volume":"1498","author":"AM Schmidt","year":"2000","unstructured":"Schmidt, A. M., Yan, S. D., Yan, S. F. & Stern, D. M. The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta. 1498, 99\u2013111. https:\/\/doi.org\/10.1016\/S0167-4889(00)00087-2 (2000).","journal-title":"Biochim. Biophys. Acta"},{"key":"58915_CR9","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.106.621854","volume":"114","author":"A Goldin","year":"2006","unstructured":"Goldin, A., Beckman, J. A., Schmidt, A. M. & Creager, M. A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114, 597\u2013605. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.621854 (2006).","journal-title":"Circulation"},{"key":"58915_CR10","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00726-010-0773-2","volume":"42","author":"R Ramasamy","year":"2012","unstructured":"Ramasamy, R., Yan, S. F. & Schmidt, A. M. Advanced glycation endproducts: from precursors to RAGE: round and round we go. Amino Acids. 42, 1151\u20131161. https:\/\/doi.org\/10.1007\/s00726-010-0773-2 (2012).","journal-title":"Amino Acids"},{"key":"58915_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.molmet.2013.11.006","volume":"3","author":"A Stirban","year":"2014","unstructured":"Stirban, A., Gawlowski, T. & Roden, M. Vascular effects of advanced glycation end products: clinical effects and molecular mechanisms. Mol. Metab. 3, 94\u2013108. https:\/\/doi.org\/10.1016\/j.molmet.2013.11.006 (2014).","journal-title":"Mol. Metab."},{"key":"58915_CR12","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.cardiores.2004.03.001","volume":"63","author":"G Basta","year":"2004","unstructured":"Basta, G., Schmidt, A. M. & De Caterina, R. Advanced glycation end products and vascular inflammation. Cardiovasc. Res. 63, 582\u2013592. https:\/\/doi.org\/10.1016\/j.cardiores.2004.03.001 (2004).","journal-title":"Cardiovasc. Res."},{"key":"58915_CR13","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s00125-004-1451-2","volume":"47","author":"R Meerwaldt","year":"2004","unstructured":"Meerwaldt, R. et al. Simple non-invasive assessment of advanced glycation end product accumulation. Diabetologia 47, 1324\u20131330. https:\/\/doi.org\/10.1007\/s00125-004-1451-2 (2004).","journal-title":"Diabetologia"},{"key":"58915_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/postgradmedj-2016-134579","volume":"93","author":"M Da Semedo","year":"2017","unstructured":"Da Semedo, M. Skin autofluorescence, a non-invasive marker of advanced glycation end products: clinical relevance and limitations. Postgrad. Med. J. 93, 289\u2013294. https:\/\/doi.org\/10.1136\/postgradmedj-2016-134579 (2017).","journal-title":"Postgrad. Med. J."},{"key":"58915_CR15","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.2337\/dc05-2173","volume":"29","author":"HL Lutgers","year":"2006","unstructured":"Lutgers, H. L. et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care. 29, 2654\u20132659. https:\/\/doi.org\/10.2337\/dc05-2173 (2006).","journal-title":"Diabetes Care"},{"key":"58915_CR16","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.2337\/dc08-2328","volume":"32","author":"HL Lutgers","year":"2009","unstructured":"Lutgers, H. L. et al. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score. Diabetes Care. 32, 1024\u20131029. https:\/\/doi.org\/10.2337\/dc08-2328 (2009).","journal-title":"Diabetes Care"},{"key":"58915_CR17","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.2174\/0929867043364342","volume":"11","author":"AJ Smit","year":"2004","unstructured":"Smit, A. J. & Lutgers, H. L. The clinical relevance of advanced glycation end products (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Curr. Med. Chem. 11, 2767\u20132784. https:\/\/doi.org\/10.2174\/0929867043364342 (2004).","journal-title":"Curr. Med. Chem."},{"key":"58915_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1089\/dia.2009.0113","volume":"12","author":"M Koetsier","year":"2010","unstructured":"Koetsier, M. et al. Reference values of skin autofluorescence. Diabetes Technol. Ther. 12, 399\u2013403. https:\/\/doi.org\/10.1089\/dia.2009.0113 (2010).","journal-title":"Diabetes Technol. Ther."},{"issue":"1","key":"58915_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1186\/s12957-025-04094-5","volume":"23","author":"Y Wen","year":"2025","unstructured":"Wen, Y. et al. Prognostic significance of the CALLY index for cancer risk and survival: evidence from NHANES 2001\u20132018. World J. Surg. Oncol. 23 (1), 431. https:\/\/doi.org\/10.1186\/s12957-025-04094-5 (2025).","journal-title":"World J. Surg. Oncol."},{"key":"58915_CR20","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1177\/00031348241248693","volume":"90","author":"K Nakashima","year":"2024","unstructured":"Nakashima, K. et al. Usefulness of the C-reactive protein\u2013albumin\u2013lymphocyte (CALLY) index as a prognostic indicator for patients with gastric cancer. Am. Surg. 90, 2703\u20132709. https:\/\/doi.org\/10.1177\/00031348241248693 (2024).","journal-title":"Am. Surg."},{"key":"58915_CR21","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1186\/s12885-025-14074-3","volume":"25","author":"B Wu","year":"2025","unstructured":"Wu, B. et al. Integrating inflammation, nutrition, and immunity: the CALLY index as a prognostic tool in digestive system cancers. BMC Cancer. 25, 672. https:\/\/doi.org\/10.1186\/s12885-025-14074-3 (2025).","journal-title":"BMC Cancer"},{"key":"58915_CR22","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1016\/j.asjsur.2024.03.054","volume":"47","author":"Y Takeda","year":"2024","unstructured":"Takeda, Y. et al. Prognostic usefulness of the C-reactive protein\u2013albumin\u2013lymphocyte (CALLY) index as a novel biomarker in patients undergoing colorectal cancer surgery. Asian J. Surg. 47, 3492\u20133498. https:\/\/doi.org\/10.1016\/j.asjsur.2024.03.054 (2024).","journal-title":"Asian J. Surg."},{"key":"58915_CR23","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","volume":"25","author":"D Furman","year":"2019","unstructured":"Furman, D. et al. Chronic inflammation in the etiology of disease across the life span. Nat. Med. 25, 1822\u20131832. https:\/\/doi.org\/10.1038\/s41591-019-0675-0 (2019).","journal-title":"Nat. Med."},{"key":"58915_CR24","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.rdc.2009.10.004","volume":"35","author":"T Sokka","year":"2009","unstructured":"Sokka, T. & Pincus, T. Joint counts to assess rheumatoid arthritis for clinical research and usual clinical care: advantages and limitations. Rheum. Dis. Clin. North. Am. 35, 713\u2013722. https:\/\/doi.org\/10.1016\/j.rdc.2009.10.004 (2009).","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"58915_CR25","doi-asserted-by":"publisher","first-page":"722","DOI":"10.4149\/bll_2015_142","volume":"116","author":"A Kucuk","year":"2015","unstructured":"Kucuk, A. et al. Neutrophil-to-lymphocyte ratio is involved in the severity of ankylosing spondylitis. Bratisl. Lek. Listy 116, 722\u2013725. https:\/\/doi.org\/10.4149\/bll_2015_142 (2015).","journal-title":"Bratisl. Lek. Listy"},{"issue":"1","key":"58915_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s41927-025-00499-7","volume":"9","author":"J Zhang","year":"2025","unstructured":"Zhang, J. et al. The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index exhibits an L-shaped association with all-cause mortality in rheumatoid arthritis patients: A retrospective cohort study. BMC Rheumatology 947. https:\/\/doi.org\/10.1186\/s41927-025-00499-7 (2025).","journal-title":"BMC Rheumatology"},{"key":"58915_CR27","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1080\/17520363.2024.2430942","volume":"18","author":"O Kilic","year":"2024","unstructured":"Kilic, O. et al. Immune nutrition indices are associated with disease activity in rheumatoid arthritis: A cross-sectional study. Biomark. Med. 18, 1093\u20131102. https:\/\/doi.org\/10.1080\/17520363.2024.2430942 (2024).","journal-title":"Biomark. Med."},{"key":"58915_CR28","doi-asserted-by":"publisher","first-page":"376","DOI":"10.5152\/ArchRheumatol.2025.25012","volume":"40","author":"A Ozdogan Bircan","year":"2025","unstructured":"Ozdogan Bircan, A. et al. Immunonutritional biomarkers in primary Sj\u00f6gren\u2019s syndrome disease activity: CALLY index and HALP score. Archives of Rheumatology 40, 376\u2013384. https:\/\/doi.org\/10.5152\/ArchRheumatol.2025.25012 (2025).","journal-title":"Archives of Rheumatology"},{"key":"58915_CR29","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00125-018-4769-1","volume":"62","author":"RP van Waateringe","year":"2019","unstructured":"van Waateringe, R. P. et al. Skin autofluorescence predicts cardiovascular disease and mortality. Diabetologia. 62, 269\u2013280. https:\/\/doi.org\/10.1007\/s00125-018-4769-1 (2019).","journal-title":"Diabetologia"},{"key":"58915_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-026-08024-y","author":"B Torun","year":"2026","unstructured":"Torun, B. & \u00c7igilo\u011flu, A. The CALLY index as an indicator of inflammatory burden across clinical phases of familial mediterranean fever. Clinical Rheumatology https:\/\/doi.org\/10.1007\/s10067-026-08024-y (2026).","journal-title":"Clinical Rheumatology"},{"issue":"2122","key":"58915_CR31","doi-asserted-by":"publisher","first-page":"w13580","DOI":"10.4414\/smw.2012.13580","volume":"142","author":"L Obici","year":"2012","unstructured":"Obici, L. & Merlini, G. AA amyloidosis: Basic knowledge, unmet needs and future treatments. Swiss Med. Wkly. 142w13580. https:\/\/doi.org\/10.4414\/smw.2012.13580 (2012).","journal-title":"Swiss Med. Wkly."},{"key":"58915_CR32","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMoa070265","volume":"356","author":"HJ Lachmann","year":"2007","unstructured":"Lachmann, H. J. et al. Natural history and outcome in systemic AA amyloidosis. N. Engl. J. Med. 356, 2361\u20132371. https:\/\/doi.org\/10.1056\/NEJMoa070265 (2007).","journal-title":"N. Engl. J. Med."},{"key":"58915_CR33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/ard.61.1.79","volume":"61","author":"C Korkmaz","year":"2002","unstructured":"Korkmaz, C., Ozdogan, H., Kasapcopur, O. & Yazici, H. Acute phase response in familial Mediterranean fever. Ann. Rheum. Dis. 61, 79\u201381. https:\/\/doi.org\/10.1136\/ard.61.1.79 (2002).","journal-title":"Ann. Rheum. Dis."},{"key":"58915_CR34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4330\/wjc.v4.i4.90","volume":"4","author":"Z Hegab","year":"2012","unstructured":"Hegab, Z. Role of advanced glycation end products in cardiovascular disease. World J. Cardiol. 4, 90\u2013102. https:\/\/doi.org\/10.4330\/wjc.v4.i4.90 (2012).","journal-title":"World J. Cardiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58915-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58915-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58915-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:17:22Z","timestamp":1786357042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58915-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["58915"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-58915-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from all participants prior to their inclusion in the study.","order":1,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Bursa City Hospital (Approval No: 2026-3\/8; Date: 4 February 2026). The study was registered at ClinicalTrials.gov (Identifier: NCT07439341).","order":2,"name":"Ethics","label":"Institutional review board statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24725"}}